Does Botulinum Toxin Type A Interact with Letibotulinumtoxina Wlbg?
CDI records a moderate classification for Botulinum Toxin Type A and Letibotulinumtoxina Wlbg. The stored summary is: Botulinum neurotoxin products administered at the same time or within several months of LETYBO may potentiate excessive neuromuscular weakness. Use caution and monitor closely. The mechanism involves additive neuromuscular blockade effects. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Botulinum Toxin Type A Class
- Acetylcholine Release Inhibitor
- Letibotulinumtoxina Wlbg Class
- Acetylcholine Release Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Additive neuromuscular blockade effects
What To Tell Your Doctor or Pharmacist
If you are taking Botulinum Toxin Type A and your doctor is considering prescribing Letibotulinumtoxina Wlbg (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider